Taysha Gene Therapies to Announce Q2 2024 Financial Results and Host Call on August 12

Taysha Gene Therapies, Inc., a biotechnology firm headquartered in Dallas and listed on Nasdaq under the ticker symbol TSHA, has announced its financial results for the second quarter ending June 30, 2024. The company also plans to hold a corporate update conference call and webcast on Monday, August 12, 2024, at 8:30 AM Eastern Time. This meeting aims to provide insights into the company's recent progress and future direction.

Taysha Gene Therapies specializes in developing gene therapies based on adeno-associated virus (AAV) technology for treating severe monogenic diseases that affect the central nervous system (CNS). Its lead clinical program, TSHA-102, is currently being developed to treat Rett syndrome. Rett syndrome is a rare neurodevelopmental disorder that presently lacks approved therapies targeting the genetic cause of the disease.

The company is committed to creating transformative medications to meet significant unmet medical needs, intending to significantly enhance the quality of life for patients and their caregivers. Taysha leverages the extensive experience of its management team in gene therapy development and commercialization. This expertise, combined with an efficient manufacturing process and a clinically validated AAV9 capsid, aims to expedite the journey from laboratory research to clinical treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!